Last reviewed 2026-05-14 · How we verify

[carbonyl-^11C]GW842166

GlaxoSmithKline · Phase 1 active Small molecule

[carbonyl-^11C]GW842166 is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 1 development.

At a glance

Generic name	[carbonyl-^11C]GW842166
Sponsor	GlaxoSmithKline
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[carbonyl-^11C]GW842166 CI brief — competitive landscape report
[carbonyl-^11C]GW842166 updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI

Frequently asked questions about [carbonyl-^11C]GW842166

What is [carbonyl-^11C]GW842166?

[carbonyl-^11C]GW842166 is a Small molecule drug developed by GlaxoSmithKline.

Who makes [carbonyl-^11C]GW842166?

[carbonyl-^11C]GW842166 is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is [carbonyl-^11C]GW842166 in?

[carbonyl-^11C]GW842166 is in Phase 1.

Manufacturer: GlaxoSmithKline — full pipeline
Compare: [carbonyl-^11C]GW842166 vs similar drugs
Pricing: [carbonyl-^11C]GW842166 cost, discount & access